Mesirow Financial Investment Management Inc. Has $18.39 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Mesirow Financial Investment Management Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 125,696 shares of the company’s stock after selling 2,051 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Johnson & Johnson were worth $18,392,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Innealta Capital LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $27,000. Christopher J. Hasenberg Inc bought a new stake in shares of Johnson & Johnson during the first quarter worth $31,000. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $44,000. Finally, Fairfield Financial Advisors LTD bought a new stake in shares of Johnson & Johnson during the second quarter worth $46,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on JNJ. TD Cowen decreased their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. The Goldman Sachs Group decreased their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. Finally, Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Trading Up 0.9 %

NYSE:JNJ opened at $167.02 on Tuesday. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The business’s 50-day moving average price is $159.98 and its two-hundred day moving average price is $153.98. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $401.96 billion, a price-to-earnings ratio of 10.41, a PEG ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the prior year, the firm posted $2.80 earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.